May 10, 2022 AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference
April 13, 2022 AlzeCure’s rights issue is registered and the trading in Paid Subscription Shares ceases
April 11, 2022 AlzeCure carries out a set-off issue in connection with ACD440 entering phase II and Acturum Life investing in the company
March 17, 2022 AlzeCure presents new data at AD/PD meeting on NeuroRestore’s positive effect on mitochondrial function
March 8, 2022 AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease
February 8, 2022 AlzeCure is moving towards Phase IIa clinical trial with ACD440 based on guiding response from the FDA
January 27, 2022 Novel data in Alzstatin Alzheimer’s project presented at the 11th Pharmaceutical Profiling meeting
January 18, 2022 AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference
January 11, 2022 AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function
